肝门部胆管癌现代治疗

摘要/Abstract

摘要： 背景肝门区胆管癌(Hilar cholangiocarcinoma, HC)是源于肝外左右肝管或左右肝管汇合处的胆道腺癌, 迄今对其治果不佳。本文通过相关文献回顾, 综述肝门胆管癌的治疗方法、治疗时机选择和术前检查评估。其中, 治愈性治疗包括局部切除、部分肝切除、联合尾状叶切除及肝门区淋巴结清扫、原位肝移植。局部切除仅适于局限于胆管壁及Bismuth I级乳头状癌;对HC大部分选择部分肝切除联合尾状叶切除及肝门区淋巴结清扫。这些术式可根据门静脉栓塞, 腹腔镜分期以及腹腔镜下超声等进行选择。但术前胆道引流存在争议;尽管Mayo指南中对无法切除的肝门胆管癌行原位肝移植的建议已被广泛接受, 但肝门胆管癌自体移植结果令人失望。缓解治疗方案包括分流手术, 内镜或经皮支架置入术, 光动力学治疗, 腔内短距离放射治疗, 外照射治疗以及系统性化疗。结论恰当的R0切除是治疗的主要目标和选择, 对无法切除的肝门胆管癌病人, 治疗目标为改善生存质量。

关键词: 肝门部胆管癌, 治疗进展

Abstract: Background Hilar cholangiocarcinoma (HC) originates in the main extrahepatic left or right duct or their confluence It’s still considered to be hard to treat or cure.Data source:We reviewed the medical literatures on HC and we analysis the relevant and updated information in a concise and easy-to-read manner.Result The selection and timing of management options for HC are determined by the diagnosis,the underlying liver function,the general condition of the patients and the stage of the disease.Nowadays,the treatment of HC can be divided into curative and palliative treatment.For the curative treatment,local excision should only be used on Bismuth I papillary carcinoma.Combined partial hepatectomy should be combined with caudate lobe resection and porta-hepatis lymph node dissection.The results of these surgical selections can be improved by portal vein embolization,staging laparoscopy and laparoscopic ultrasound.The role of preoperative biliary drainage is controversial.Autotransplantation for HC gave disappointing results while the Mayo Protocol of chemoradiation for selecting patients with unresectable HC for orthotopic liver transplantation has been widely accepted.Palliative treatment included bypass surgery,endoscopic or percutaneous stenting,photodynamic therapy,intraluminal brachytherapy,and external radiation and systemic therapy.Conclusions:Adequate surgery with R0 resection should be the main goal of treatment.For patients with unresectable HC,treatment aims to improve the quality and quantity of their survival.

Key words: Hilar cholangiocarcinoma, Curative therapy

中图分类号:

林锐, 刘中砚, 陈泉宁, 施宝民. 肝门部胆管癌现代治疗[J]. 外科研究与新技术, 2012, 1(2): 165-168.

Lin Rui, Liu Zhong-Yan, Chen Quan-Ning, Shi Bao-Ming. Current therapy for hilar cholelangiocarcinoma[J]. 外科研究与新技术, 2012, 1(2): 165-168.

参考文献

[1] Klatskin G.Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatic.An unusual tumor with distinctive clinical and pathological features [J].Am J Med,1965,38(3):241-256.
[2] Bismuth H,Corlette MB.Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver[J].Surg Gynecol Obstet,1975,140(2):170-178.
[3] Edge SB,Byrd DR,Compton CC,et,al.AJCC Cancer Staging Manual[M].7th ed.New York:Springer,2010.
[4] Jarnagin WR,Fong Y,DeMatteo RP,et al.Staging,resectability,and outcome in 225 patients with hilar cholangiocarcinoma[J].Ann Surg,2001,234(4):507-519.
[5] Deoliveira ML,Schulick RD,Nimura Y,et al.New staging system and a registry for perihilar cholangiocarcinoma[J].Hepatology,2011,53(5):1363-1371.
[6] Capussotti L,Vigano L,Ferrero A,et.al.A.Local surgical resection of hilar cholangiocarcinoma:is there still a place?[J].HPB (Oxford),2008,10(3):174-178.
[7] Tsao JI,Nimura Y,Kamiya J,et al.Management of hilar cholangiocarcinoma:comparison of an American and a Japanese experience[J].Ann Surg,2000,232(2):166-174.
[8] Ikeyama T,Nagino M,Oda K,et al.Surgical approach to bismuth Type I and II hilar cholangiocarcinomas:audit of 54 consecutive cases[J].Ann Surg,2007,246(6):1052-1057.
[9] Neuhaus P,Jonas S,Bechstein WO,et al.Extended resections for hilar cholangiocarcinoma[J].Ann Surg,1999,230(3):808-819.
[10] Dinant S,Gerhards MF,Busch OR,et,al.The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma[J].HPB (Oxford),2005,7(4):263-267.
[11] Ishizawa T,Hasegawa K,Sano K,et.al.Selective versus total biliary drainage for obstructive jaundice caused by a hepatobiliary malignancy[J].Am J Surg,2007,193(2):149-154.
[12] Sewnath ME,Karsten TM,Prins MH,et.al.A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice[J].Ann Surg,2002,236(1):17-27.
[13] Liu F,Li Y,Wei Y,et.al.Preoperative biliary drainage before resection for hilar cholangiocarcinoma:whether or not? A systematic review[J].Dig Dis Sci,2011,56(6):663-672.
[14] 何建平,朱运龙等胆管癌的诊断及治疗进展[J].昆明医学院学报,2012,20(3):247-250.
[15] Weber SM,DeMatteo RP,Fong Y,et.al.Staging laparoscopy in patients with extrahepatic biliary carcinoma.Analysis of 100 patients[J].Ann Surg,2002,235(3):392-399.
[16] Connor S,Barron E,Wigmore SJ,et.al.The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma[J].J Gastrointest Surg,2005,9(4):476-480.
[17] Pichlmayr R,Bretschneider HJ,Kirchner E,et al.Ex situ operation on the liver.A new possibility in liver surgery[J].Langenbecks Arch Chir,1988,373(2):122-126.
[18] Chui AK,Rao AR,Wong J,et al.Ex situ ex vivo liver resection,partial liver autotransplantation for advanced hilar cholangiocarcinoma:a case report[J].Transplant Proc,2003,35(1):402-403.
[19] Rosen CB,Heimbach JK,Gores GJ.Liver transplantation for cholangiocarcinoma[J].Transpl Int,2010,23(5):692-697.
[20] Chen XP,Lau WY,Huang ZY,et al.Extent of liver resection for hilar cholangiocarcinoma[J].Br J Surg,2009,96(2):1167-1175.
[21] Geller A.Klatskin tumor—palliative therapy:the jury is still out or may be not yet in[J].Gastrointest Endosc,2009,69(1):63-65.
[22] Moss AC,Morris E,Leyden J,et al.Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction[J].Eur J Gastroenterol Hepatol,2007,19(12):1119-1124.
[23] Baron TH.Palliation of malignant obstructive jaundice[J].astroenterol Clin North Am,2006,35(11):101-112.
[24] Perdue DG,Freeman ML,DiSario JA,et al.Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction:a prospective multicenter observational cohort study[J].J Clin Gastroenterol,2008,42(9):1040-1046.
[25] Baer HU,Rhyner M,Stain SC,et al.The effect of communication between the right and left liver on the outcome of surgical drainage for jaundice due to malignant obstruction at the hilus of the liver[J].HPB Surg,1994,8(1):27-31.
[26] Zoepf T,Jakobs R,Arnold JC,et al.Palliation of nonresectable bile duct cancer:improved survival after photodynamic therapy[J].Am J Gastroenterol,2005,100(11):2426-2430.
[27] Quyn AJ,Ziyaie D,Polignano FM,et al.Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma[J].HPB (Oxford),2009,11(7):570-577.
[28] Válek V,Kysela P,Kala Z,et al.Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma:a prospective randomised study[J].Eur J Radiol,2007,62(2):175-179.
[29] Takamura A,Saito H,Kamada T,et al.Intraluminal low-dose-rate ¹⁹²Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma[J].Int J Radiat Oncol Biol Phys,2003,57(5):1357-1365.
[30] Nakeeb A,Pitt HA.Radiation therapy,chemotherapy and chemoradiation in hilar cholangiocarcinoma[J].HPB (Oxford),2005,7(4):278-282.